Literature DB >> 3766314

Hepatoprotection by malotilate against carbon tetrachloride-alcohol-induced liver fibrosis.

C P Siegers, V Pauli, G Korb, M Younes.   

Abstract

Subchronic treatment of male rats with carbon tetrachloride (CCl4, twice weekly 0.2 ml/kg p.o.) and feeding a 5% alcohol solution instead of drinking water led to a nearly complete liver cirrhosis in all animals within 4 weeks. This was also documented by a three fold increase in hepatic total hydroxyproline content. Steatosis was quantified by enhanced liver triglyceride concentrations and acute necroses by increments of serum enzyme activities (GPT, SDH). Daily oral treatment with malotilate (100 mg/kg) totally prevented the development of liver cirrhosis, hepatic hydroxyproline accumulation and increases in serum enzyme activities induced by CCl4-alcohol. In cianidanol-treated rats (100 mg/kg p.o.) only portoseptal fibrosis was seen, however hydroxyproline and triglyceride accumulation as well as enhanced serum enzyme activities were not suppressed. D-penicillamine (300 mg/kg p.o.) and colchicine (50 micrograms/kg i.p.) failed to protect rats against CCl4-alcohol induced fibrosis, necrosis and steatosis in this model.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3766314     DOI: 10.1007/bf01964970

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  9 in total

1.  A specific method for the analysis of hydroxyproline in tissues and urine.

Authors:  D J PROCKOP; S UDENFRIEND
Journal:  Anal Biochem       Date:  1960-11       Impact factor: 3.365

2.  Effect of (+)-catechin on purified prolyl hydroxylase and on collagen synthesis in skin fibroblasts in culture.

Authors:  M Lonati-Galligani; L Galligani; G C Fuller
Journal:  Biochem Pharmacol       Date:  1979-09-01       Impact factor: 5.858

3.  Further studies on the in vivo effect of diisopropyl 1,3-dithiol-2-ylidenemalonate (NKK-105) on the liver microsomal drug oxidation system in rats.

Authors:  M Katoh; M Kitada; T Satoh; H Kitagawa; T Sugimoto; T Kasai
Journal:  Biochem Pharmacol       Date:  1981-10       Impact factor: 5.858

Review 4.  Is cirrhosis of the liver experimentally produced by CCl4 and adequate model of human cirrhosis?

Authors:  R Pérez Tamayo
Journal:  Hepatology       Date:  1983 Jan-Feb       Impact factor: 17.425

Review 5.  Interactions between ethanol and other hepatotoxic agents.

Authors:  O Strubelt
Journal:  Biochem Pharmacol       Date:  1980-06-01       Impact factor: 5.858

6.  Sex differences in the susceptibility of rats to carbon tetrachloride--alcohol-induced liver injury.

Authors:  C P Siegers; W Reichl; M Younes
Journal:  Agents Actions       Date:  1984-01

7.  Effects of dithiocarb and (+)-catechin against carbon tetrachloride-alcohol-induced liver fibrosis.

Authors:  C P Siegers; M Völpel; G Scheel; M Younes
Journal:  Agents Actions       Date:  1982-12

8.  Stimulatory effect of cytochrome b5 induced by p-nitroanisole and diisopropyl 1,3-dithiol-2-ylidenemalonate on rat liver microsomal drug hydroxylations.

Authors:  S Kawata; T Sugiyama; K Seki; S Tarui; M Okamoto; T Yamano
Journal:  J Biochem       Date:  1982-07       Impact factor: 3.387

9.  Effect of diisopropyl 1,3-dithiol-2-ylidenemalonate on microsomal electron transport system in rat liver.

Authors:  M Katoh; M Kitada; T Satoh; H Kitagawa; T Sugimoto; T Kasai
Journal:  J Pharmacobiodyn       Date:  1980-05
  9 in total
  2 in total

1.  Protective Effects of Hydrolyzed Nucleoproteins from Salmon Milt against Ethanol-Induced Liver Injury in Rats.

Authors:  Akiko Kojima-Yuasa; Mayu Goto; Eri Yoshikawa; Yuri Morita; Hirotaka Sekiguchi; Keita Sutoh; Koji Usumi; Isao Matsui-Yuasa
Journal:  Mar Drugs       Date:  2016-12-19       Impact factor: 5.118

2.  Mallotus furetianus extract protects against ethanol-induced liver injury via the activation of the cAMP-PKA pathway.

Authors:  Eri Yoshikawa; Isao Matsui-Yuasa; Xuedan Huang; Yoshinori Kobayashi; Akiko Kojima-Yuasa
Journal:  Food Sci Nutr       Date:  2020-06-10       Impact factor: 2.863

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.